Partnership Opportunities
Connect With a Global Community of Experts:
Engage with a Highly Targeted Audience
Connect directly with senior leaders in oligonucleotide chemistry, delivery, CMC, safety, and regulatory strategy, all actively seeking partners to overcome challenges in capacity, timelines, bioavailability, and quality to accelerate their programs.
Showcase Your Chemistry, Delivery & Development Expertise
Highlight your solutions in innovative oligo design, precision delivery, and scalable manufacturing, demonstrating how you tackle industry bottlenecks such as long development timelines, off-target effects, and difficulties translating candidates into the clinic.
Position Your Brand as a Trusted Strategic Partner
Build credibility as a go-to collaborator who delivers what matters most: competitive cost, predictable timelines, transparency, and uncompromising quality, helping advance safer, more effective RNA-based medicines.
What to Expect:
Distinguish Yourself from the Crowd
Stand out to senior decision-makers by showcasing your innovative solutions, thought leadership, and ability to tackle the biggest challenges in oligonucleotide therapeutics.
Demonstrate Your Expertise
Present your work within our program, participate in a panel discussion or showcase your solutions in a bespoke exhibition booth to demonstrate your company’s unique capabilities.
Gain Market Intelligence
Stay ahead of industry trends by hearing directly from KOLs, get insights and competitor strategies to shape your organisations competitive edge.
Meet New Clients
Expand your client base by networking face-toface with dedicated attendees actively seeking solutions to overcome challenges in the development of oligonucleotide therapeutics
Key Services & Solutions:
Our attendees from Novo Nordisk, Dyne Therapeutics, Genentech and more are looking for service and solution providers with capabilities in the below areas but not limited to:
- Providing oligonucleotide synthesis capabilities at both R&D and commercial scale-up stages of drug development.
- Raw starting materials for synthesising oligos
- Clinical CRO expertise addressing inherent toxicity and safety challenges
- This community need leading CDMOs for ASO and siRNA synthesis, to ensure top-quality production and robust analytical assessments.
- State of the art in vivo models, highlight the uniqueness and reliability of your models, ensuring robust preclinical data.
Attending Companies Include:
Get in Touch
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.
Tazeen Kapadia
Senior Partnerships Director